Online inquiry

IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9177MR)

This product GTTS-WQ9177MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9177MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6208MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CR4098
GTTS-WQ1826MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ8248MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HLX10
GTTS-WQ4895MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BYM338
GTTS-WQ624MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ10384MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY2127399
GTTS-WQ15318MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ9335MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA INCAGN-01876
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW